SCHEMBL533225

SCHEMBL533225

CC(C)([O])CF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834936 0.78
SCHEMBL477967 0.78
SCHEMBL477719 0.78
SCHEMBL1040252 0.70
SCHEMBL17729820 0.68
SCHEMBL681449 0.67
SCHEMBL9054 0.67
SCHEMBL23062 0.67
SCHEMBL620238 0.67
SCHEMBL2498264 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114583268-A Lithium ion battery electrolyte and application thereof 深圳市研一新材料有限责任公司 2022-06-03 CN claimed
US-20240199692-A1 POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT TAISHO PHARMACEUTICAL CO., LTD. (JP) 2024-06-20 US disclosed
CN-118165031-A Nitrile compound, electrolyte, secondary battery and device 蔚来电池科技(安徽)有限公司 2024-06-11 CN disclosed
CN-117105916-B Benzofuran compound and medical application thereof 希格生科(深圳)有限公司 2024-01-16 CN disclosed
CN-117105916-A Benzofuran compound and medical application thereof 希格生科(深圳)有限公司 2023-11-24 CN disclosed
WO-2023204170-A1 PROPHYLACTIC OR THERAPEUTIC AGENT, FOR LUNG INFLAMMATION AND FIBROSIS, CONTAINING COMPOUND HAVING MMP2 INHIBITORY ACTIVITY AS ACTIVE INGREDIENT 大正製薬株式会社 2023-10-26 WO disclosed
CN-116936928-A Lithium ion battery electrolyte additive and preparation method and application thereof 深圳市研一新材料有限责任公司 2023-10-24 CN disclosed
EP-3595072-B1 ADDITIVE FOR NON-AQUEOUS ELECTROLYTIC SOLUTIONS, NON-AQUEOUS ELECTROLYTIC SOLUTION, AND ELECTRICAL STORAGE DEVICE SUMITOMO SEIKA CHEMICALS (JP) 2023-10-04 EP disclosed
CN-116535379-B Compound and medical application thereof 希格生科(深圳)有限公司 2023-09-19 CN disclosed
CN-116535379-A Compound and medical application thereof 希格生科(深圳)有限公司 2023-08-04 CN disclosed
CN-102421777-A Azacyclospiro derivatives as HSL inhibitors HOFFMANN LA ROCHE 2012-04-18 CN disclosed
US-8158652-B2 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases MSD K.K. (JP) 2012-04-17 US disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed
US-20110054172-A1 PYRIDYLAMINOACETIC ACID COMPOUND UBE CORPORATION (JP) 2011-03-03 US disclosed
EP-2264009-A1 PYRIDYLAMINOACETIC ACID COMPOUND Ube Industries, Ltd. (JP) 2010-12-22 EP disclosed
US-20080269287-A1 Substituted Pyridone Derivative MSD K.K. (JP) 2008-10-30 US disclosed
EP-1820797-A1 SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-22 EP disclosed
US-5672723-A SELECTIVE HYDROLYSIS OR ALCOHOLYSIS OF A MIXTURE OF 1-ACYL-1-ALKYLHYDRAZINE AND 1-ACYL-2-ALKYLHYDRAZINE USING AN ACID CATALYST TO OBTAIN AN ACID OR ESTER AND THE STABLE 1-ACYL-2-ALKYLHYRAZINE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1997-09-30 US disclosed
EP-0639558-B1 Process for preparation of 1-acyl-2-substituted-hydrazines NIPPON KAYAKU KK (JP) 1996-10-23 EP disclosed
EP-0639558-A1 Process for preparation of 1-acyl-2-substituted-hydrazines Nippon Kayaku Kabushiki Kaisha (JP) 1995-02-22 EP disclosed